NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
Clinical Trials
3 trialsNCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00550277 2021-11-23
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed